Influenza (Flu)

1. Clinical Overview

Summary

Influenza is an acute viral respiratory infection caused by Influenza viruses A and B, representing one of the most significant global public health challenges. Influenza A is responsible for seasonal epidemics and all known pandemics, while Influenza B causes seasonal outbreaks with generally milder disease. [1,2]

The illness is characterised by abrupt onset of systemic and respiratory symptoms: high fever (38-40°C), severe myalgia, headache, profound fatigue, dry cough, and sore throat. Unlike the common cold, influenza is distinguished by prominent systemic symptoms that can leave patients bedridden for several days. The pathophysiology involves viral replication in respiratory epithelium triggering extensive cytokine release, which accounts for the dramatic constitutional symptoms. [3,4]

While most healthy adults experience self-limiting illness resolving within 5-7 days, influenza causes substantial morbidity and mortality in high-risk populations: adults ≥65 years, pregnant women, individuals with chronic medical conditions (particularly cardiorespiratory disease, diabetes, immunosuppression), and those with severe obesity (BMI ≥40). These groups account for the majority of hospitalisations and deaths, with case-fatality rates up to 100-fold higher than in young healthy adults. [5,6]

Complications include primary viral pneumonia (rapidly progressive, high mortality), secondary bacterial pneumonia (typically 3-7 days after initial improvement), acute respiratory distress syndrome (ARDS), myocarditis, and exacerbations of underlying chronic conditions. Bacterial superinfection is most commonly caused by Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, and Haemophilus influenzae. The biphasic pattern of initial improvement followed by clinical deterioration is pathognomonic for secondary bacterial pneumonia. [7,8]

Management is primarily supportive in uncomplicated cases. Neuraminidase inhibitors (oseltamivir, zanamivir) reduce symptom duration by approximately 1 day when initiated within 48 hours of symptom onset and are recommended for all hospitalised patients and high-risk outpatients regardless of illness duration. Meta-analyses demonstrate that oseltamivir reduces complications by 25-44% in high-risk patients and mortality by approximately 25% in hospitalised patients. [9,10]

Annual vaccination remains the cornerstone of prevention, with quadrivalent vaccines targeting two Influenza A strains (H1N1, H3N2) and two Influenza B lineages (Victoria, Yamagata). Vaccine effectiveness varies by season (typically 40-60%) depending on antigenic match, but consistently reduces severity, complications, and mortality even when protection against infection is suboptimal. Vaccination also reduces cardiovascular events, with 15-45% reduction in myocardial infarction risk documented in multiple studies. [11,12]

Clinical Pearls

"Sudden Onset, Know the Hour": Patients with influenza can often identify the precise hour symptoms began—a key distinguishing feature from other respiratory infections which develop gradually. This abrupt onset reflects the rapid viral replication kinetics and explosive cytokine response characteristic of influenza pathogenesis.

"Influenza ≠ Common Cold": Cold (rhinovirus) = Gradual onset over 1-2 days, predominantly nasal symptoms (rhinorrhoea, sneezing), minimal systemic upset, no/low-grade fever. Influenza = Abrupt onset within hours, high fever (> 38.5°C), severe myalgia, profound prostration, prominent dry cough. This distinction is clinically crucial for appropriate antiviral use and patient counselling.

"The 48-Hour Rule (With Exceptions)": Neuraminidase inhibitors are most effective when started within 48 hours of symptom onset for symptom reduction. However, treatment should NOT be withheld beyond 48 hours in hospitalised or deteriorating patients—mortality benefit persists in severe disease regardless of timing. [10]

"Biphasic Fever = Bacterial Superinfection": Initial improvement followed by clinical deterioration with recurrent fever, productive cough, and respiratory distress suggests secondary bacterial pneumonia—typically occurs 3-7 days after symptom onset. This pattern reflects initial viral epithelial damage creating conditions for bacterial invasion.

"Vaccinate the Vulnerable Annually": Priority groups include ≥65 years, pregnant women (any trimester), chronic respiratory/cardiac/renal/hepatic/neurological/diabetes/immunosuppression, BMI ≥40, healthcare workers, and care home residents. Vaccination reduces not only influenza infection but also cardiovascular mortality.

"Pregnancy is High Risk": Physiological changes in pregnancy (reduced functional residual capacity, altered cell-mediated immunity, increased oxygen consumption) increase risk of severe influenza 4-7 fold. Vaccination is safe and strongly recommended in any trimester, protecting both mother and infant through transplacental antibodies. [13]

"Oseltamivir Dosing in Renal Impairment": Requires dose adjustment—CrCl 30-60: 30mg BD; CrCl 10-30: 30mg OD; CrCl less than 10: 30mg after each dialysis session. Failure to adjust dosing can lead to drug accumulation and neuropsychiatric adverse effects.

"The Cytokine Storm Paradox": Severe influenza outcomes paradoxically occur in those with robust immune responses (young adults in 1918 pandemic, H5N1 cases). Excessive interferon and pro-inflammatory cytokine production drives ARDS and multi-organ failure. This explains why immunomodulation has been explored as adjunctive therapy in severe cases. [14]

---

2. Epidemiology

Global Burden

Influenza causes 3-5 million cases of severe illness and 290,000-650,000 respiratory deaths globally each year, with pandemic years substantially exceeding these figures. In temperate regions, seasonal epidemics occur in winter months (November-March in Northern Hemisphere; May-September in Southern Hemisphere), while tropical regions may experience year-round transmission or bimodal peaks. The winter seasonality is driven by absolute humidity, temperature, and indoor crowding patterns. [1,15]

In the United Kingdom, annual influenza epidemics result in an average of 10,000-30,000 excess deaths, with the vast majority (> 90%) occurring in adults ≥65 years. Excess all-cause mortality during severe seasons can increase by 20-40% above baseline, predominantly from cardiovascular and respiratory causes. The 2017-2018 season was particularly severe, with approximately 50,000 excess deaths associated with influenza and H3N2 predominance. [16]

Demographics and Risk Factors

Virus Types and Subtypes

Currently Circulating Strains (2025-2026 Season):

• A(H1N1)pdm09 — Descendant of 2009 pandemic strain. Generally less severe than H3N2. More common in younger adults. Associated with primary viral pneumonia in severe cases.
• A(H3N2) — Undergoes more rapid antigenic drift due to higher mutation rate and egg adaptation during vaccine production; often associated with severe seasons, particularly affecting elderly. Vaccine effectiveness typically lower against H3N2.
• B/Victoria — Predominant B lineage since 2020. Generally causes milder disease than Influenza A.
• B/Yamagata — Declining circulation since 2020; possibly extinct due to COVID-19 public health measures. May be removed from future vaccine formulations.

High-Risk Groups for Severe Disease

Mortality Data

• Case Fatality Rate (CFR): less than 0.1% in healthy adults; 1-5% in high-risk groups; up to 30% in ICU with ARDS
• Excess Mortality: 90% of deaths occur in ≥65 age group. Cardiovascular deaths account for 30-50% of excess mortality (often attributed to other causes).
• Leading Causes of Death: Pneumonia (primary viral or secondary bacterial 40%), ARDS (15%), cardiovascular events (30%), exacerbation of underlying disease (15%)
• Pandemic Mortality: Highly variable. 1918 H1N1 ("Spanish Flu"): 50-100 million deaths, CFR ~2.5%, unusual W-shaped mortality curve with peak in young adults. 2009 H1N1: ~150,000-575,000 deaths globally, CFR ~0.02%, mostly in younger individuals and those with obesity.

---

3. Pathophysiology

Virus Structure

Influenza viruses are single-stranded, negative-sense RNA viruses belonging to the Orthomyxoviridae family. The genome consists of 8 gene segments encoding 10-14 proteins (depending on strain and counting splice variants). This segmented structure allows genetic reassortment when two different strains co-infect the same cell—the molecular mechanism underlying antigenic shift and pandemic emergence. [2,18]

Key Surface Glycoproteins:

Internal Proteins:

• M2 (Matrix-2): Proton channel; acidifies virion interior during uncoating. Target of adamantanes (amantadine/rimantadine)—now obsolete due to > 95% resistance in circulating strains (S31N mutation).
• M1 (Matrix-1): Structural protein; mediates assembly and budding.
• PB1, PB2, PA: Polymerase complex (RNA-dependent RNA polymerase); replicates viral genome and transcribes mRNA via cap-snatching from host mRNA. Target of baloxavir (cap-dependent endonuclease inhibitor). PA-I38T mutation confers baloxavir resistance.
• NP (Nucleoprotein): Encapsidates viral RNA; type-specific antigen used in diagnostic assays.
• NS1 (Non-structural protein 1): Interferon antagonist; major virulence factor. Blocks RIG-I signalling and mRNA processing.
• NEP/NS2: Nuclear export protein; mediates export of viral ribonucleoproteins from nucleus.

Antigenic Variation

Avian Reservoir: Wild aquatic birds (particularly ducks, geese) are the natural reservoir for all 18 Influenza A subtypes. Avian strains typically cause asymptomatic intestinal infection in birds. Human pandemics arise when avian viruses acquire ability to: (1) bind human-type α2,6-linked sialic acid receptors (requires H protein mutations like E190D, G225D), (2) transmit efficiently between humans (requires polymerase adaptations for replication at cooler human upper airway temperatures). Direct avian-to-human transmission (e.g., H5N1, H7N9) causes severe disease but lacks sustained human-to-human transmission. [19]

Pathogenesis: Infection Cycle

1. Entry and Attachment

• Inhalation of infectious droplets (> 5µm, travel less than 1-2m) or aerosols (less than 5µm, remain airborne) containing 10²-10⁵ infectious virions
• Haemagglutinin binds to α2,6-linked sialic acid (Neu5Acα2,6Gal) receptors on respiratory epithelial cells (predominantly trachea, bronchi, bronchioles; alveoli in severe cases)
• Human upper airway predominantly expresses α2,6 receptors; lower airway has mixed α2,3 and α2,6 expression
• Receptor-mediated endocytosis → Virus enters cell in clathrin-coated vesicle

2. Uncoating and Replication

• Endosome acidification (pH 5-6) triggers conformational change in H protein → Fusion of viral and endosomal membranes
• M2 protein (proton channel) acidifies virion interior → Dissociation of M1 from viral ribonucleoproteins (vRNPs)
• vRNPs transported to nucleus (unique among RNA viruses)
• Polymerase complex (PB1-PB2-PA) synthesises:
  • Positive-sense cRNA (complementary RNA) from negative-sense viral RNA (vRNA)
  • vRNA from cRNA templates (genome replication)
  • mRNA via "cap-snatching" (PA endonuclease cleaves 5' caps from host pre-mRNA, steals caps for viral mRNA)
• Viral proteins synthesised in cytoplasm; H, N, M2 trafficked to plasma membrane via Golgi
• vRNPs exported from nucleus via NEP/NS2

3. Assembly and Budding

• Viral components assemble at apical plasma membrane (preferentially lipid rafts enriched in cholesterol and sphingolipids)
• M1 protein coordinates assembly beneath H/N-enriched membrane domains
• Budding occurs at apical surface → Progeny virions released into airway lumen
• Each infected cell produces 10³-10⁴ virions before death (8-12 hours post-infection)
• Viral replication peaks 48-72 hours post-infection, corresponding to peak symptoms

4. Release and Spread

• Neuraminidase cleaves sialic acid, releasing progeny virions from host cell surface and preventing viral aggregation
• Without NA, virions remain tethered to cell surface and aggregate (non-infectious clumps)
• Neuraminidase inhibitors (oseltamivir) block this step → Localize infection, reduce viral spread
• Virus spreads to adjacent epithelial cells → Descending infection (initially upper airway, can progress to bronchioles/alveoli in severe cases)

5. Tissue Damage

• Direct cytopathic effect: Viral replication exhausts cellular resources, disrupts cellular functions → Apoptosis and necrosis of infected epithelial cells
• Loss of ciliated epithelium → Impaired mucociliary clearance → Pooling of secretions → Predisposition to bacterial superinfection
• Epithelial denudation exposes basement membrane → Bacterial adherence facilitated (particularly S. aureus and S. pneumoniae)
• Epithelial damage peaks at 5-7 days, regeneration takes 2-4 weeks for complete repair
• Severe cases: Diffuse alveolar damage (DAD) → Hyaline membranes, pulmonary oedema, ARDS

6. Immune Response

Innate Immunity (Hours to Days):

• Pattern recognition receptors (TLR3, TLR7, TLR8, RIG-I, MDA5) detect viral RNA
• Interferon (IFN-α/β) production → Upregulation of interferon-stimulated genes (ISGs) → Antiviral state in neighbouring cells (inhibits viral replication)
• Inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-8, MIP-1α) → Systemic symptoms (fever via hypothalamic IL-1/IL-6 action, myalgia via prostaglandin E2 and direct cytokine effects, malaise)
• Neutrophil and macrophage recruitment → Clear infected cells and debris
• "Cytokine Storm" in severe cases (excessive IL-6, TNF-α, IFN-γ, IL-1β) → Vascular leak, pulmonary oedema, ARDS, multi-organ failure. More common in H5N1 and 1918 H1N1 (young adults paradoxically). [14]

Adaptive Immunity (Days to Weeks):

• CD8+ T cells (cytotoxic T lymphocytes) recognise viral peptides on MHC-I → Kill infected cells. Target conserved internal proteins (NP, M1) → Cross-reactive protection against different subtypes (heterosubtypic immunity).
• CD4+ T cells (helper T cells) provide help for antibody production and cytotoxic responses
• B cells produce antibodies:
  • "IgM (days 5-7): First antibody response"
  • "IgG (days 10-14): Neutralises virus, prevents re-infection with same strain. Mainly targets H protein (head domain). Subtype-specific."
  • "Mucosal IgA (secretory): Provides local upper airway protection, neutralises virus before cell entry"
• Memory B and T cells → Long-term immunity to that specific strain (and closely related drifted variants)
• Immunity is strain-specific (antibodies to H1N1 do not protect against H3N2 or drifted H1N1 variants)

Why Complications Occur

---

4. Differential Diagnosis

Comparison of Acute Respiratory Infections

Other Important Differentials

Red Flags: When to Suspect Complications

---

5. Clinical Presentation

Classic Presentation (Uncomplicated Influenza)

Symptoms

Natural History and Phases

Viral Shedding:

• Begins: 24-48 hours before symptom onset (explains high attack rates, difficult to contain)
• Peak: Days 2-3 of illness (highest transmission risk)
• Duration: 5-7 days in healthy adults; up to 10 days in children; weeks to months in immunocompromised (important for infection control—extended isolation required)
• Transmission Risk: Highest in first 3-5 days of illness. Droplet precautions until 24-48h fever-free.

Physical Examination Findings

General Examination

Head and Neck

Respiratory Examination

KEY POINT: Chest examination is NORMAL in uncomplicated influenza. Any abnormality (crackles, bronchial breathing, dullness) indicates complication (pneumonia) and warrants CXR and consideration for admission/antibiotics.

Presentations in Special Populations

Elderly (≥65 years)

• May have atypical presentation: Less prominent fever (may be absent or low-grade despite severe infection), reduced myalgia/headache
• Functional decline may be most noticeable feature: inability to perform ADLs, falls, reduced mobility
• Delirium common presenting symptom (30-50% of elderly with influenza have altered mental status)
• Falls may occur (multifactorial: delirium, dehydration, orthostatic hypotension)
• Higher risk of complications even with mild initial symptoms (30-50% develop pneumonia)
• Lower vaccine efficacy due to immunosenescence (30-40% vs 60-80% in young adults; high-dose or adjuvanted vaccines recommended)
• Polypharmacy considerations (drug interactions with oseltamivir rare, but renal function often impaired → dose adjustment)
• Frailty predicts worse outcomes (Clinical Frailty Scale ≥5 has 5× mortality risk)

Pregnant Women

• Same symptoms as non-pregnant adults initially, but progression can be rapid
• Higher risk of severe disease: 4-7× increased hospitalisation risk. Risk present from conception, but highest in 3rd trimester (4-fold increased risk).
• Warning signs requiring urgent assessment:
  • Dyspnoea or chest pain (may indicate pneumonia or pulmonary oedema)
  • Reduced fetal movements (fetal hypoxia)
  • Vaginal bleeding (placental abruption, preterm labour)
  • Contractions or pelvic pressure (preterm labour)
  • Reduced urine output (pre-eclampsia, dehydration)
  • Severe headache or visual disturbances (pre-eclampsia)
• Oseltamivir is safe in pregnancy—benefits outweigh theoretical risks. Should be started immediately in symptomatic pregnant women. Category C (animal studies show adverse effects, but human benefits likely outweigh risks). No teratogenicity detected in human studies.
• Vaccination safe in any trimester—strongly recommended (reduces maternal hospitalisation 40%, reduces infant influenza 63% in first 6 months via transplacental antibody transfer)
• Fetal risks: preterm labour (2× risk), low birth weight, stillbirth (rare, severe maternal illness)
• Postpartum: Risk persists for 2 weeks postpartum (include in high-risk group)

Immunocompromised (HIV CD4 less than 200, chemotherapy, transplant, biologics)

• May have prolonged symptoms (> 2 weeks, sometimes months)
• Prolonged viral shedding (weeks to months) → Infection control: Extended isolation required (droplet precautions until 2 consecutive negative PCRs 24h apart, not just symptom-based)
• Lower respiratory tract disease more common (bronchiolitis, pneumonia in 30-50%)
• Risk of oseltamivir resistance developing during treatment (H275Y mutation in N1, especially with suboptimal dosing or prolonged shedding)
• May require longer treatment courses (10 days rather than standard 5 days; some require suppressive therapy)
• Vaccine response blunted—consider serological testing (anti-H antibody titres) to confirm seroconversion. May benefit from double-dose vaccination (limited evidence).
• Higher mortality: 5-20% case-fatality in severely immunosuppressed (haematological malignancy worst prognosis)
• Consider combination antiviral therapy in severe cases (oseltamivir + IV peramivir or zanamivir), though evidence limited

Patients with Chronic Respiratory Disease (Asthma, COPD, Bronchiectasis)

• Exacerbations of underlying disease common (30-50%)
• Increased dyspnoea, wheeze, sputum production (change in colour/volume)
• Higher risk of bacterial superinfection (impaired clearance mechanisms)
• May require increased bronchodilators (↑ salbutamol frequency, add ipratropium), corticosteroids (prednisolone 30-40mg OD for 5-7 days), consider antibiotics if purulent sputum/CRP elevated
• COPD patients: 2-4× hospitalisation risk. Respiratory failure may require NIV or intubation. Oxygen therapy carefully (target SpO₂ 88-92% to avoid CO₂ retention).
• Asthma patients: Risk of severe exacerbation. Peak flow monitoring. May require ↑ inhaled corticosteroids. Beware zanamivir (inhaled, can cause bronchospasm—use oseltamivir instead).
• Bronchiectasis: High risk of bacterial superinfection (Pseudomonas, H. influenzae). May require sputum culture-directed antibiotics.

Patients with Diabetes Mellitus

• Hyperglycaemia during acute illness (stress response with cortisol/catecholamine release, reduced oral intake, cytokine effects on insulin resistance)
• Risk of diabetic ketoacidosis (type 1) or hyperosmolar hyperglycaemic state (type 2), particularly if nausea/vomiting leads to missed insulin/medications
• Increased insulin requirements (may need 20-50% increase during acute illness)
• "Sick day rules": Never stop insulin. Check blood glucose 4-hourly. Check ketones (urine or blood) if glucose > 15 mmol/L. Maintain hydration. Seek help if vomiting/unable to eat.
• Impaired immune function (neutrophil dysfunction, impaired chemotaxis) → Higher infection rates, slower recovery
• Monitor blood glucose frequently (at least 4-6 hourly during acute illness)
• 3× hospitalisation risk, 6× mortality risk compared to non-diabetics

---

6. Investigations

Diagnostic Approach

Clinical diagnosis is often sufficient during documented influenza season (local surveillance data showing influenza circulation) in patients with compatible symptoms (sudden onset, fever, myalgia, cough). Laboratory confirmation is NOT required for management in uncomplicated outpatient cases.

Testing IS indicated for:

1. Hospitalised patients (confirm diagnosis, guide antiviral use, infection control, discontinue empirical antibiotics if influenza confirmed and no bacterial co-infection)
2. High-risk outpatients where result will influence antiviral treatment decision (though increasingly, treat empirically without waiting for results)
3. Atypical or severe illness (differential diagnosis, exclude other pathogens)
4. Outbreak investigation / public health surveillance (confirm influenza, determine subtype, detect novel strains, monitor resistance)
5. ICU patients with severe respiratory illness (multiplex respiratory PCR panel to identify pathogen and guide therapy)
6. Pregnancy, immunocompromised, or other high-risk groups if diagnosis unclear

Influenza-Specific Tests

Specimen Collection:

• Nasopharyngeal swab/aspirate preferred (highest viral load, 80-90% sensitivity)
• Throat swab acceptable (slightly lower sensitivity 70-80%)
• Nasal swab (mid-turbinate) acceptable for rapid tests
• BAL (bronchoalveolar lavage) in intubated patients (highest sensitivity, can detect when upper airway negative)
• Timing: Best within first 3-4 days of illness (peak viral shedding). Viral load decreases after day 5 → False negatives possible with all tests (including PCR).
• Technique: Insert swab to posterior nasopharynx (parallel to palate, not upwards), rotate 10-15 seconds, withdraw. Immediate transport in viral transport medium (VTM) or universal transport medium (UTM). Keep at 4°C if delayed processing.

Multiplex Respiratory Panels

Many laboratories now use multiplex PCR panels (e.g., BioFire FilmArray, Luminex xTAG) that detect 15-25 respiratory pathogens simultaneously:

Viruses Detected:

• Influenza A (with subtyping H1/H3), Influenza B
• SARS-CoV-2 (all variants)
• Respiratory Syncytial Virus (RSV) A/B
• Parainfluenza 1, 2, 3, 4
• Human metapneumovirus (hMPV)
• Rhinovirus/Enterovirus
• Adenovirus
• Coronavirus (HKU1, NL63, 229E, OC43)
• Human bocavirus (children)

Bacteria Detected (some panels):

• Mycoplasma pneumoniae
• Chlamydia pneumoniae
• Bordetella pertussis
• Legionella pneumophila (on some panels)

Advantages:

• Single test, rapid (1-2 hours), comprehensive
• Detects co-infections (10-30% of influenza patients have co-detection, clinical significance uncertain)
• Useful in ICU/immunocompromised (higher rate of atypical/multiple pathogens)
• Informs infection control (isolate RSV, influenza in separate rooms)

Disadvantages:

• Cost (£100-200 per test vs £20-50 for single-pathogen PCR)
• Potential for co-detection of colonising organisms (rhinovirus, coronavirus detection may represent asymptomatic carriage, especially in children)
• Does not distinguish Influenza subtypes on all panels (some only report A vs B)
• Clinical utility of knowing multiple viruses detected is uncertain (management usually unchanged)

Investigations for Complications / Severe Disease

All Hospitalised Patients

Patients with Respiratory Symptoms / Hypoxia

ICU / Critically Ill Patients

• Serial ABGs (4-6 hourly or continuous via arterial line): Monitor respiratory failure progression, guide ventilator settings, assess metabolic acidosis
• Lactate (serial): Tissue perfusion marker, sepsis severity. Target less than 2 mmol/L.
• Troponin (if myocarditis or MI suspected): Elevated in 10-20% of severe influenza (myocarditis, MI, type 2 MI from demand ischaemia)
• BNP/NT-proBNP (if heart failure suspected): Distinguishes cardiogenic vs non-cardiogenic pulmonary oedema. > 400 pg/mL (BNP) or > 900 pg/mL (NT-proBNP) suggests cardiac cause.
• Coagulation screen (PT, APTT, fibrinogen, D-dimer): DIC in severe sepsis (↑ PT/APTT, ↓ fibrinogen, ↑ D-dimer, ↓ platelets)
• CK (Creatine Kinase) (if rhabdomyolysis suspected): Severe myalgia, dark urine, AKI. CK > 1000 U/L (normal less than 200) diagnostic. Treat with IV fluids.
• Bronchoscopy with BAL (bronchoalveolar lavage) (if diagnosis uncertain, immunocompromised, treatment failure): Direct sampling of lower airway. Send for bacterial culture, fungal culture, viral PCR, Pneumocystis jirovecii PCR (if HIV/immunosuppressed). BAL more sensitive than upper airway swabs in intubated patients.
• Echocardiography (if haemodynamic instability, myocarditis suspected): Assess LV function (myocarditis → global hypokinesis, ↓ ejection fraction), pericardial effusion, RV dysfunction (PE, ARDS)

Point-of-Care Tests (POC)

Advantages:

• Rapid results (15-30 min) enable immediate clinical decision-making
• Reduce unnecessary antibiotic use (if influenza confirmed and no bacterial features, avoid antibiotics)
• Facilitate infection control measures (isolate influenza-positive patients, cohort nursing)
• Improve antiviral prescribing (patients more likely to receive oseltamivir if rapid test positive)
• Emergency Department utility: High (triage, disposition decisions)

Limitations:

• Lower sensitivity than laboratory PCR (rapid antigen tests 50-70%, molecular POC 85-95% vs lab PCR 90-95%)
• Operator-dependent (specimen collection quality critical)
• More expensive per test (rapid molecular £30-50 vs lab PCR £20-30, though lab PCR has infrastructure costs)
• Negative result does NOT exclude influenza (especially with rapid antigen tests)—clinical judgment and local epidemiology still required. If high clinical suspicion, treat as influenza regardless of negative rapid test.
• False positives rare but occur (cross-reactivity, contamination)

Recommendation: In high-prevalence settings (winter, known influenza circulation), treat based on clinical diagnosis. POC testing most useful when result will change management (e.g., decide whether to start oseltamivir in borderline high-risk patient, or decide whether to discharge vs admit).

---

7. Management

Management Algorithm

         SUSPECTED INFLUENZA
         (Winter, Abrupt onset, Fever, Myalgia, Cough)
                       ↓
         ASSESS SEVERITY + RISK FACTORS
         - Respiratory distress? (RR > 20, SpO₂ less than 92%, dyspnoea, accessory muscles)
         - Dehydration? (Reduced intake, ↓ urine output, dry mucosa, ↑ urea)
         - Altered mental status? (Confusion, drowsiness—especially elderly)
         - High-risk group? (Age ≥65, pregnancy, chronic disease, immunocompromised, BMI ≥40)
         - Complications? (Pneumonia on exam/CXR, bacterial superinfection)
                       ↓
         SEVERITY STRATIFICATION
      ┌──────────────────┴──────────────────┐
   MILD/MODERATE                        SEVERE / HIGH-RISK / COMPLICATED
   (Healthy adults, no complications)   (Complications, high-risk, hypoxia, dehydration)
      ↓                                      ↓
   OUTPATIENT MANAGEMENT               ADMIT TO HOSPITAL
   - Supportive care                   - Oxygen therapy (target SpO₂ 94-98%, or 88-92% if COPD)
   - Antipyretics (paracetamol/ibuprofen)  - IV fluids (0.9% saline or Hartmann's, correct dehydration)
   - Rest, hydration (2-3L/day)        - Continuous monitoring (obs 4-hourly minimum, NEWS2 score)
   - Safety-netting (red flags)        - Neuraminidase inhibitors (oseltamivir 75mg BD × 5 days, start immediately)
   - Antivirals if high-risk AND less than 48h  - Investigations (FBC, U&E, CRP, CXR, influenza PCR, blood cultures if septic)
   - Avoid work/school 24-48h after    - Antibiotics if bacterial superinfection (co-amoxiclav ± clarithromycin)
     fever resolves                    - VTE prophylaxis (LMWH as per local protocol)
                                       - Consider ICU if severe hypoxia/shock/multi-organ failure

Admission Criteria

Consider Hospital Admission if:

Respiratory:

• SpO₂ less than 92% on room air (or less than 88% if known COPD with chronic hypoxia)
• Respiratory rate > 30/min (severe tachypnoea)
• Respiratory distress (use of accessory muscles, intercostal recession, inability to speak in full sentences)
• Suspected pneumonia (clinical or radiological)

Haemodynamic:

• Systolic BP less than 90 mmHg (or > 40 mmHg drop from baseline)
• Pulse > 125/min (severe tachycardia, not explained by fever alone)

Metabolic/Systemic:

• Inability to maintain oral intake (vomiting, dysphagia, reduced conscious level)
• Severe dehydration (clinical signs: dry mucosa, reduced skin turgor, oliguria, ↑ urea disproportionate to creatinine)
• Altered mental status (confusion, drowsiness, delirium—especially elderly)
• Temperature > 40°C (rarely, very high fever may warrant observation)

High-Risk Patient with Worsening Symptoms:

• Age ≥65 years with clinical deterioration (even without severe parameters—lower threshold)
• Pregnancy (any trimester) with concerning symptoms (dyspnoea, chest pain, reduced fetal movements)
• Significant exacerbation of chronic disease (COPD, asthma, heart failure, diabetes with DKA/HHS)
• Immunocompromised with suspected pneumonia or deterioration

Social Factors:

• Unable to cope at home (lives alone, frail, inadequate support)
• Inability to re-attend if deteriorates (transport issues, remote location)
• Clinical concern (senior clinician gestalt—"does not look right")

NICE Pneumonia Severity Score (CURB-65) if Pneumonia Suspected:

• Confusion (AMT ≤8 or new disorientation)
• Urea > 7 mmol/L
• Respiratory rate ≥30/min
• Blood pressure (systolic less than 90 or diastolic ≤60)
• 65 years or older
• Score 0-1: Outpatient (mortality less than 3%)
• Score 2: Consider admission (mortality 9%)
• Score ≥3: Admit (mortality 15-40%), consider ICU

Supportive Care (All Patients)

Antiviral Therapy

Neuraminidase Inhibitors

Oseltamivir Dose Adjustments:

Failure to adjust dosing in renal impairment: Drug accumulation → Neuropsychiatric adverse effects (delirium, hallucinations, abnormal behaviour, especially in children/adolescents). Always calculate CrCl (Cockcroft-Gault equation) before prescribing.

Cap-Dependent Endonuclease Inhibitor

When to Give Antivirals: Evidence-Based Indications

TREAT (Regardless of Symptom Duration, Even if > 48h)

1. All hospitalised patients with confirmed or suspected influenza (do not wait for test results—start empirically)
2. Severe or progressive illness at any stage (worsening dyspnoea, hypoxia, confusion, haemodynamic instability)
3. Pneumonia or lower respiratory tract involvement (clinical or radiological)
4. ICU admission for influenza complications (ARDS, shock)
5. Immunocompromised patients (any severity, start immediately)

Rationale: Mortality benefit persists even if started > 48h in severe disease. [10]

TREAT (If Within 48 Hours of Symptom Onset AND High-Risk)

High-Risk Outpatients (UK NICE / PHE Guidance):

• Age ≥65 years
• Pregnancy (any trimester) or up to 2 weeks postpartum
• Chronic respiratory disease (asthma requiring inhaled steroids, COPD, bronchiectasis, ILD, cystic fibrosis)
• Chronic cardiac disease (CHF, IHD, congenital heart disease, valvular disease)
• Diabetes mellitus (type 1 or 2)
• Chronic kidney disease (CKD 3-5, eGFR less than 60, dialysis, nephrotic syndrome)
• Chronic liver disease (cirrhosis, chronic hepatitis)
• Chronic neurological disease (stroke, TIA, dementia, Parkinson's, MS, MND, cerebral palsy, epilepsy, learning disabilities)
• Immunosuppression (HIV, chemotherapy, transplant, biologics, corticosteroids > 20mg/day for > 2 weeks, asplenia)
• Severe obesity (BMI ≥40 kg/m²)
• Residents of care homes or long-stay facilities
• Haematological malignancy

Rationale: Oseltamivir started within 48h reduces symptom duration by 1 day, complications by 25-44%, and mortality in high-risk patients. [9,10]

DO NOT ROUTINELY TREAT

• Healthy adults (less than 65 years, no comorbidities) with uncomplicated influenza
• Mild illness in low-risk individuals (though can offer if patient requests and within 48h)
• Rationale: Antivirals reduce symptom duration by approximately 16-21 hours (1 day) in this group. Modest benefit. Self-limiting illness. Cost-effectiveness concerns (£20-30 per course). Number needed to treat (NNT) to prevent 1 day of symptoms: ~15. Most healthy adults prefer to avoid medication for marginal benefit.

Clinical Judgment: Shared decision-making. Some healthy adults may choose antiviral for faster return to work (e.g., healthcare worker, critical job role). Offer information, patient decides.

Evidence for Antiviral Efficacy

Oseltamivir (Meta-Analyses and RCTs): [9,10,20]

• Reduces symptom duration by 16-21 hours (95% CI 8-31h) if started within 48h in healthy adults (NNT ~15)
• Reduces symptom duration by ~26 hours in high-risk patients
• Reduces complications (pneumonia, hospitalisation, sinusitis, otitis media) by 25-44% in high-risk patients (NNT ~18)
• Reduces mortality in hospitalised patients by approximately 25% (OR 0.75, 95% CI 0.66-0.86; NNT ~55) [10]
• Reduces ICU admission by 30-40%
• No benefit for symptom duration if started > 48h in uncomplicated illness, BUT mortality benefit persists in severe disease regardless of timing (start even if > 48h in hospitalised patients)
• Well tolerated: nausea/vomiting most common (5-10%, usually mild, take with food to reduce)

Zanamivir:

• Similar efficacy to oseltamivir for symptom reduction (1-day reduction)
• May have lower resistance rates (no H275Y-equivalent mutation widely reported)
• Bronchospasm risk limits use in respiratory disease patients (15-20% of asthmatics develop bronchospasm)
• Inhaled delivery less convenient (especially in acutely ill, children, elderly)

Baloxavir:

• Reduces symptom duration by 24-48 hours (1-2 days) in phase 3 trials (similar to oseltamivir)
• More rapid viral load reduction than oseltamivir (median 24h vs 72h to undetectable virus)
• Single dose more convenient (improves compliance vs 5-day oseltamivir course)
• Resistance emergence in 10-15% during treatment (PA I38T/M mutation), especially H3N2 (23% resistance in one trial). Clinical significance unclear (resistant viruses still cleared, symptoms resolved, but concerns about transmission of resistant virus).
• Limited data in high-risk groups (pregnant, immunocompromised, elderly)
• More expensive (£50-100 per course vs £20-30 oseltamivir)
• Not routinely recommended in UK (oseltamivir remains first-line)

Antiviral Resistance

Key Point: Resistance more likely in:

• Immunocompromised patients (prolonged viral replication provides selection pressure, subtherapeutic drug levels in some compartments)
• Patients receiving suboptimal dosing (renal impairment without dose adjustment → excessive levels; under-dosing → resistance emergence)
• Children (higher viral loads, longer shedding, more prone to resistance with baloxavir)
• Specific subtypes: H1N1 (H275Y oseltamivir resistance), H3N2 (baloxavir I38T resistance)

Antibiotic Therapy

Antibiotics are NOT indicated for uncomplicated influenza (viral infection). Inappropriate antibiotic use contributes to resistance, adverse effects (allergy, C. difficile), and unnecessary cost.

Indications for Antibiotics:

1. Suspected Secondary Bacterial Pneumonia

Clinical Features:

• Clinical deterioration after initial improvement ("biphasic illness"—pathognomonic, days 3-7)
• New productive cough with purulent sputum (green/yellow/brown, increased volume)
• New focal chest signs (crackles, bronchial breathing, dullness to percussion) or consolidation on CXR
• High fever (> 38.5°C) persisting > 5-7 days or recurrent after initial resolution
• Pleuritic chest pain (suggests pneumococcal pneumonia)
• Haemoptysis (suggests S. aureus necrotising pneumonia)
• Elevated inflammatory markers: WCC > 15 × 10⁹/L (neutrophilia), CRP > 100 mg/L, procalcitonin > 0.5 µg/L

2. Empirical Antibiotic Regimens (Community-Acquired Pneumonia Post-Influenza)

Outpatient (Mild-Moderate, CRB-65 Score 0-1):

• First-line: Co-amoxiclav 625mg TDS PO × 5-7 days (covers S. pneumoniae, H. influenzae, S. aureus)
• Penicillin allergy: Doxycycline 200mg loading dose, then 100mg OD PO × 5-7 days (or Levofloxacin 500mg OD if severe allergy)
• Add if atypical suspected (Mycoplasma, Legionella): Clarithromycin 500mg BD PO × 7 days

Inpatient (Moderate-Severe, CRB-65 Score ≥2):

• First-line: Co-amoxiclav 1.2g TDS IV + Clarithromycin 500mg BD IV/PO × 7-10 days
• Penicillin allergy: Levofloxacin 500mg BD IV × 7-10 days (respiratory fluoroquinolone, broad cover including atypicals)
• Cover for S. aureus if necrotising pneumonia (cavitation on CXR, haemoptysis, rapid progression, MRSA risk factors): Add Flucloxacillin 2g QDS IV (or Vancomycin 15-20mg/kg BD IV if MRSA risk or penicillin allergy; target trough 15-20 mg/L)

ICU (Severe Pneumonia, Septic Shock):

• Broad-spectrum: Piperacillin-tazobactam 4.5g TDS IV + Clarithromycin 500mg BD IV
• MRSA cover: Add Vancomycin or Linezolid 600mg BD IV
• De-escalate based on culture results and clinical response

Duration:

• Oral: 5-7 days (uncomplicated)
• IV: 7-10 days (severe, initially IV then switch to oral once improving, afebrile 24-48h, able to tolerate oral)

3. Pathogens in Post-Influenza Bacterial Pneumonia

Key Point: Staphylococcus aureus post-influenza pneumonia is particularly devastating (necrotising, cavitation, high mortality). Have high index of suspicion if haemoptysis, rapid deterioration, cavitation on imaging. Start anti-staphylococcal therapy early (flucloxacillin or vancomycin).

Other Pharmacological Therapies

Management of Specific Complications

Primary Viral Pneumonia / ARDS

• ICU admission (high mortality 30-50%, requires organ support)
• Mechanical ventilation (may require early intubation—do not delay if hypoxia worsening despite high-flow oxygen)
• ARDS-protocol ventilation: Low tidal volumes (6 mL/kg ideal body weight), plateau pressure less than 30 cmH₂O, PEEP 10-15 cmH₂O, FiO₂ titrated to SpO₂ 88-95%, permissive hypercapnia (pH > 7.2 acceptable)
• Oseltamivir (standard dose 75mg BD, though some use higher dose 150mg BD in severe cases—no evidence, but theoretical benefit from animal models; not routinely recommended)
• Prone positioning if severe ARDS (PaO₂/FiO₂ less than 150 mmHg; 12-16 hours per day; improves oxygenation and mortality)
• ECMO (Extracorporeal Membrane Oxygenation) in refractory cases (PaO₂/FiO₂ less than 80 despite optimisation, or pH less than 7.2 despite ventilation; transfer to ECMO centre; mortality 40-60% but survival better than without ECMO in selected patients)
• Empirical antibiotics (difficult to exclude bacterial co-infection clinically; most clinicians give co-amoxiclav + clarithromycin even if suspected pure viral)
• Avoid high-dose corticosteroids (no benefit in influenza ARDS, may prolong viral shedding; controversial—some centres use methylprednisolone 1mg/kg/day if refractory ARDS, but evidence limited)

Secondary Bacterial Pneumonia

• Antibiotics as above (co-amoxiclav ± clarithromycin, add flucloxacillin/vancomycin if necrotising/S. aureus suspected)
• Drainage if empyema develops (chest drain insertion, CT-guided if loculated, surgical referral if failed medical management)
• May require ICU support if severe (septic shock, respiratory failure)
• Source control: Consider bronchoscopy if lung abscess (rare), surgical debridement if necrotising (very rare)

Myocarditis

• Supportive care (bed rest, monitor telemetry for arrhythmias)
• Treat heart failure if develops: Diuretics (furosemide), ACE-inhibitor (ramipril, after acute phase), beta-blocker (bisoprolol, after acute phase, start low dose)
• Avoid exertion for 3-6 months (risk of arrhythmias, sudden cardiac death with exertion during myocarditis recovery)
• Monitor: Troponin (serial, should downtrend), ECG (watch for arrhythmias, conduction abnormalities), echocardiography (assess LV function—usually global hypokinesis, reduced EF; repeat at 3-6 months to assess recovery)
• Consider immunosuppression if biopsy-proven giant cell myocarditis or fulminant (rare, specialist cardiology decision)
• Cardiac MRI if diagnosis uncertain (late gadolinium enhancement, myocardial oedema)

Exacerbation of Chronic Disease

• Optimise management of underlying condition:
  • "Asthma/COPD: Increase bronchodilators (salbutamol, ipratropium), add corticosteroids (prednisolone 30-40mg OD × 5-7 days), consider antibiotics if purulent sputum (doxycycline, co-amoxiclav). Oxygen if hypoxic (target SpO₂ 88-92% in COPD). NIV if type 2 respiratory failure."
  • "Heart failure: Diuretics (furosemide 40-80mg IV/PO, increase dose if insufficient diuresis), vasodilators (GTN infusion if pulmonary oedema, ACE-inhibitor/ARB once stable), oxygen therapy, fluid restriction, daily weights, strict fluid balance."
  • "Diabetes: Increase insulin doses (typically 20-50% increase during acute illness), check blood glucose 4-6 hourly, check ketones if glucose > 15 mmol/L (urine or blood), IV fluids if dehydrated, treat DKA/HHS if develops (fixed-rate insulin infusion, aggressive IV fluids, potassium replacement, treat underlying infection)."

Infection Control Measures

Standard Precautions (All Healthcare Settings)

Hand Hygiene:

• Alcohol gel (60-90% alcohol) before and after patient contact (if hands not visibly soiled)
• Soap and water if hands visibly soiled or after high-risk procedures
• 5 Moments of Hand Hygiene: (1) Before patient contact, (2) Before aseptic task, (3) After body fluid exposure, (4) After patient contact, (5) After contact with patient surroundings

Personal Protective Equipment (PPE):

• Surgical mask (Type IIR, fluid-resistant) when within 1-2 metres of patient
• Gloves for direct patient contact (change between patients)
• Apron for direct patient contact
• Eye protection (goggles or face shield) if risk of splashes (suctioning, vomiting, coughing patient)
• FFP3 mask (N95 equivalent, fit-tested) for aerosol-generating procedures (intubation, extubation, bronchoscopy, open suctioning, manual ventilation, NIV/CPAP, high-flow nasal oxygen > 30L/min, nebulisers, CPR)

Isolation:

• Single room preferred (negative pressure if available, though not required for droplet precautions—reserve for aerosol-generating procedures)
• Cohort influenza patients together if single rooms unavailable (separate from other respiratory infections like COVID-19, RSV)
• Duration: Until 24-48 hours after fever resolves (without antipyretics) AND minimum 5 days from symptom onset. Immunocompromised: Extended isolation until 2 consecutive negative PCRs 24h apart (may be weeks).

Droplet vs Aerosol Transmission:

• Influenza primarily spread by droplets (> 5µm diameter, travel less than 1-2 metres, fall to ground quickly)—hence surgical masks and 1-2m distance sufficient for standard care
• Aerosol-generating procedures (AGPs) produce smaller particles (less than 5µm, remain airborne, travel > 2m)—require FFP3 masks, negative-pressure room, limit personnel present
• Controversial: Some evidence influenza can transmit via aerosols in enclosed spaces (schools, aircraft), but healthcare droplet precautions have proven effective

Healthcare Worker Considerations

• Vaccinate annually (ethical duty, protects staff and patients)—mandated in many jurisdictions (e.g., some US states require vaccination or mask-wearing for unvaccinated HCWs during influenza season)
• Exclude from work if symptomatic (fever, cough, influenza-like illness)—return after 24-48h fever-free (without antipyretics) AND able to perform duties
• Antiviral prophylaxis may be offered to unvaccinated staff during outbreaks (oseltamivir 75mg OD × 10 days post-exposure, or duration of outbreak)—but vaccination preferred
• Fit-test FFP3 masks annually (quantitative or qualitative fit-testing to ensure adequate seal)—required for AGPs
• Monitor HCW infection rates (occupational health surveillance)—high rates may indicate breakdown in infection control, need for intervention

Outbreak Control (Hospitals, Care Homes)

• Declare outbreak if ≥2 linked cases within 7 days (PHE/UKHSA notification)
• Restrict admissions to affected ward (new admissions only if essential)
• Restrict movements (patients stay in bay/room, no communal activities)
• Restrict visitors (essential visits only, provide PPE education)
• Antiviral prophylaxis for all residents/patients and staff on affected ward (oseltamivir 75mg OD × duration of outbreak)
• Enhanced cleaning (daily terminal clean of affected areas, focus on high-touch surfaces)
• Staff cohorting (dedicated staff for outbreak ward, do not rotate to other wards)
• Close ward if outbreak uncontrolled (no new admissions until 7 days after last case)

---

8. Complications

Respiratory Complications

Cardiovascular Complications

Neurological Complications

Other Complications

---

9. Prognosis and Outcomes

Uncomplicated Influenza (Healthy Adults)

Mortality Risk Stratification

Prognostic Factors (Adverse Outcomes—Hospitalisation, ICU, Death)

Demographic:

• Age ≥65 years (OR 5-10 for death vs 18-64 age group)
• Age less than 2 years (children—U-shaped mortality curve)
• Pregnancy (especially 3rd trimester; OR 4-5 for hospitalisation vs non-pregnant)

Comorbidities (Odds Ratios for Death):

• Chronic respiratory disease: OR 3-5 (COPD > asthma > ILD)
• Chronic cardiac disease: OR 3-5 (CHF > IHD)
• Diabetes mellitus: OR 3-6 (type 1 > type 2)
• Chronic kidney disease: OR 2-4 (dialysis > CKD 3-5)
• Chronic liver disease (cirrhosis): OR 5-10
• Immunosuppression: OR 5-20 (haematological malignancy >> solid organ transplant > HIV > chemotherapy)
• Severe obesity (BMI ≥40): OR 2-3
• Neurological disease (impaired cough/swallow): OR 2-4

Clinical Presentation (At Hospital Admission):

• Hypoxia: SpO₂ less than 92% on air (OR 5-10 for death; SpO₂ less than 88% OR 10-20)
• Altered mental status / Confusion (OR 5-10)
• Hypotension: Systolic BP less than 90 mmHg (OR 5-10; septic shock)
• Tachycardia: Pulse > 125/min not explained by fever (OR 2-4)
• Tachypnoea: Respiratory rate > 30/min (OR 5-10)
• Bacterial superinfection (OR 3-5; especially S. aureus necrotising pneumonia OR 10-20)
• Bilateral infiltrates on CXR (viral pneumonia; OR 5-10 vs unilateral)

Laboratory Findings (At Admission):

• Lymphopenia: Absolute lymphocyte count less than 0.6 × 10⁹/L (OR 2-3)
• Elevated CRP: > 100 mg/L (suggests bacterial superinfection; OR 2-4)
• Acute kidney injury: Creatinine > 200µmol/L or ↑ > 50% from baseline (OR 3-5)
• Elevated LDH: > 400 U/L (marker of tissue damage, ARDS; OR 2-4)
• Thrombocytopenia: Platelets less than 100 × 10⁹/L (DIC, sepsis; OR 3-5)
• Elevated troponin: > 100 ng/L (myocarditis, MI, type 2 MI; OR 2-4)
• Lactate > 2 mmol/L (tissue hypoperfusion, sepsis; OR 3-5; lactate > 4 OR 10-20)

Time to Antiviral Treatment:

• Early oseltamivir (less than 48h from symptom onset): Baseline mortality
• Late oseltamivir (> 48h): Still beneficial in hospitalised patients (OR 0.79 for death vs no treatment), but less effective than early treatment

Long-Term Sequelae

Most patients recover fully. However, a subset experience persistent symptoms or late complications:

Post-Viral Fatigue Syndrome:

• Incidence: 10-20% report fatigue lasting > 4 weeks; 5% report fatigue > 12 weeks
• Features: Persistent tiredness, reduced exercise tolerance, post-exertional malaise, difficulty concentrating ("brain fog"), sleep disturbances
• Pathophysiology: Unclear. Hypotheses: mitochondrial dysfunction, persistent immune activation, hypothalamic-pituitary-adrenal axis dysregulation
• Management: Reassurance (usually resolves 2-6 months), graded exercise therapy (gradual increase in activity), cognitive behavioural therapy if prolonged, exclude alternative causes (anaemia, thyroid dysfunction, depression). Distinguish from Chronic Fatigue Syndrome (ME/CFS) which requires symptoms > 6 months + specific diagnostic criteria.

Impaired Pulmonary Function:

• After viral pneumonia/ARDS: May have persistent restrictive lung disease (↓ FVC, ↓ DLCO), pulmonary fibrosis (ground-glass on CT → honeycombing if severe), reduced exercise tolerance
• Duration: Weeks-months for mild, permanent in severe cases (post-ARDS fibrosis in 20-30%)
• Management: Pulmonary rehabilitation, oxygen if hypoxic (home LTOT if PaO₂ less than 7.3kPa), treat any ongoing inflammation (controversial; some advocate corticosteroids if evidence of organising pneumonia), serial spirometry and CT chest to monitor

Cardiovascular Events—Increased Risk Persists Weeks-Months:

• Myocardial infarction: Risk elevated for 1-2 months post-influenza (6-10× in week 1, 2-3× in weeks 2-4, returns to baseline by 8-12 weeks). [17]
• Stroke: Increased risk for 1 month (2-3× baseline)
• Mechanism: Persistent inflammation (↑ CRP, ↑ IL-6 for weeks), plaque instability, hypercoagulable state
• Implication: Influenza vaccination reduces cardiovascular events (15-45% reduction in MI risk)—important preventive cardiology intervention [17]

Exacerbation of Chronic Disease—Return to Baseline May Take Weeks-Months:

• COPD: Lung function may not return to pre-exacerbation baseline (10-20% have permanent ↓ FEV1 after severe exacerbation)
• Asthma: Airway hyperreactivity may persist weeks (↑ ICS dose post-influenza)
• Heart failure: Decompensation may take weeks to optimise (adjust diuretics, uptitrate ACE-inhibitor/beta-blocker gradually)
• Diabetes: Glycaemic control disrupted (may require ↑ insulin doses for weeks post-illness)

Functional Decline in Elderly:

• Incidence: 20-30% of elderly hospitalised with influenza have persistent functional decline (↓ ADLs, ↓ mobility)
• Risk factors: Frailty (Clinical Frailty Scale ≥5), delirium during admission, prolonged hospitalisation (> 7 days), complications (pneumonia, falls)
• Management: Comprehensive geriatric assessment, physiotherapy, occupational therapy, home care package, consider care home if cannot cope independently

---

10. Prevention

Vaccination

Annual influenza vaccination is the single most effective preventive intervention, reducing influenza infection, severity, complications, and mortality even in seasons with suboptimal antigenic match. [11,12,21]

Vaccine Types

Vaccine Composition (Annual Update)

WHO Global Influenza Surveillance and Response System (GISRS) monitors circulating strains globally via 144 National Influenza Centres in 114 countries. Vaccine composition updated twice annually:

• February (Northern Hemisphere season, October-March)
• September (Southern Hemisphere season, May-September)

Selection Process:

1. Global surveillance identifies circulating strains (October-January for Northern Hemisphere)
2. WHO convenes expert committee (February)
3. Selects 4 strains (2 Influenza A, 2 Influenza B) based on: (a) Predominance, (b) Antigenic drift from previous vaccine, (c) Epidemiological data
4. Manufacturers produce vaccines (6-8 months) using selected strains

2025-2026 Northern Hemisphere Season Composition (Example):

• A/Victoria/4897/2022 (H1N1)pdm09-like virus (descendant of 2009 pandemic strain)
• A/Thailand/8/2022 (H3N2)-like virus (recent H3N2 clade)
• B/Austria/1359417/2021 (B/Victoria lineage)-like virus (dominant B lineage)
• B/Phuket/3073/2013 (B/Yamagata lineage)-like virus (declining circulation; may be removed future seasons)

Note: B/Yamagata has not been detected globally since March 2020 (COVID-19 NPIs may have driven extinction). Trivalent vaccines (2 A strains + 1 B strain, Victoria lineage only) under consideration.

Vaccine Effectiveness

Efficacy vs Effectiveness:

• Vaccine Efficacy (VE): Measured in randomised controlled trials (RCT) under ideal conditions
• Vaccine Effectiveness: Real-world performance (observational studies, test-negative design)

Effectiveness varies by:

1. Antigenic Match (Major Determinant):

• Well-matched seasons (vaccine strains antigenically similar to circulating strains): VE 50-70%
• Mismatched seasons (circulating strains drifted from vaccine strains): VE 10-30%
• Example: 2014-2015 season (H3N2 mismatch): VE 19% overall. 2017-2018 season (H3N2 mismatch): VE 25%. 2019-2020 season (well-matched): VE 45%.

2. Virus Subtype:

• H1N1pdm09: VE 50-70% (most seasons; well-matched, less prone to egg adaptation)
• H3N2: VE 30-40% (lower due to rapid antigenic drift + egg-adaptation mutations during vaccine production → vaccine strain differs from circulating wild-type). Egg-grown H3N2 vaccine viruses acquire mutations (e.g., in receptor-binding site) → reduced cross-reactivity.
• Influenza B: VE 50-60%

3. Age:

• Children (2-17 years): VE 60-80% (robust immune response)
• Adults (18-64 years): VE 40-60%
• Elderly (≥65 years): VE 30-40% (immunosenescence → reduced antibody response, ↓ T cell function). Solution: Adjuvanted or high-dose vaccines (VE 50-60% in elderly, superior to standard dose).

4. Prior Immunity ("Original Antigenic Sin" / Immune Imprinting):

• First influenza exposure in childhood shapes lifelong immune responses (imprinting)
• Subsequent infections/vaccinations preferentially recall memory responses to childhood strains ("back-boosting") → May reduce response to drifted strains
• Complex interactions: Prior vaccination can enhance or reduce current vaccine effectiveness depending on strains involved

Effectiveness Against Outcomes (Even When VE Against Infection is Moderate):

Key Principle: Vaccine reduces severity, complications, and mortality even when it does not completely prevent infection. Partial immunity (from vaccine or prior infection) attenuates disease.

Eligible Groups (UK NHS Funded Vaccination)

All individuals with ANY of the following (NHS-funded; free at point of care):

Age:

• Age ≥65 years (all individuals; no exclusions)

Pregnancy:

• Pregnancy (any trimester; includes 1st trimester, 2nd, 3rd)
• Up to 2 weeks postpartum (if not vaccinated during pregnancy)

Chronic Respiratory Disease:

• Asthma requiring regular inhaled corticosteroids (any dose) or previous hospital admission for asthma
• COPD (any stage; GOLD 1-4)
• Bronchiectasis
• Interstitial lung disease (ILD; pulmonary fibrosis)
• Cystic fibrosis

Chronic Cardiac Disease:

• Congestive heart failure (CHF; any stage)
• Ischaemic heart disease (IHD; previous MI, angina, coronary stents/CABG)
• Congenital heart disease (structural defects)
• Valvular disease (moderate-severe; prosthetic valves)

Chronic Kidney Disease:

• CKD stage 3-5 (eGFR less than 60 mL/min)
• Dialysis (haemodialysis, peritoneal dialysis)
• Nephrotic syndrome
• Kidney transplant

Chronic Liver Disease:

• Cirrhosis (any cause; compensated or decompensated)
• Chronic hepatitis (hepatitis B, hepatitis C)
• Alcohol-related liver disease

Chronic Neurological Disease:

• Stroke or TIA (any history)
• Dementia (Alzheimer's, vascular, Lewy body, frontotemporal)
• Parkinson's disease
• Multiple sclerosis (MS)
• Motor neurone disease (MND; ALS)
• Cerebral palsy
• Epilepsy (on medication)
• Hereditary/degenerative CNS disease
• Learning disabilities

Diabetes Mellitus:

• Type 1 diabetes
• Type 2 diabetes (any treatment; diet-controlled, oral agents, insulin)

Immunosuppression:

• HIV (any CD4 count; especially CD4 less than 200)
• Chemotherapy (current or within 6 months)
• Solid organ transplant (kidney, liver, heart, lung, pancreas; lifelong)
• Bone marrow transplant (lifelong)
• Asplenia (splenectomy, sickle cell disease, coeliac disease with hyposplenism)
• Biologics (TNF-α inhibitors—adalimumab, infliximab, etanercept; rituximab; other immunomodulators)
• Long-term corticosteroids (≥20mg prednisolone daily for > 2 weeks; or lower doses if immunosuppressive)
• Primary immunodeficiency (congenital)

Severe Obesity:

• BMI ≥40 kg/m² (morbid obesity)

Care Home Residents:

• Residents of care homes or long-stay facilities (elderly or disabled)

Carers:

• Main carer for elderly or disabled individual (receipt of Carer's Allowance, or main unpaid carer)

Healthcare Workers:

• Frontline healthcare workers (direct patient contact)
• Social care workers (care homes, domiciliary care)

Children:

• All children aged 2-16 years (school-age programme; LAIV intranasal spray)
• Children less than 2 years with clinical risk factors (as per chronic disease list above; inactivated vaccine only—LAIV not licensed less than 2 years)

Timing of Vaccination

Contraindications and Precautions

Absolute Contraindications (Inactivated Vaccine):

• Severe allergic reaction (anaphylaxis) to previous dose of influenza vaccine (rare; less than 1 per million doses)
• Severe allergic reaction to vaccine component (if known specific allergy to gelatin, antibiotics in vaccine—rare)

Absolute Contraindications (Live Attenuated Nasal Spray—LAIV):

• Immunosuppression (any cause): HIV, chemotherapy, transplant, biologics, high-dose corticosteroids (≥20mg prednisolone > 2 weeks or equivalent), primary immunodeficiency
• Pregnancy (theoretical risk of live virus to fetus; no documented cases of harm, but avoid as precaution)
• Severe asthma or active wheeze (risk of bronchospasm; defined as requiring oral corticosteroids in previous 72 hours, or hospitalisation for asthma in previous 12 months)
• Aspirin/salicylate therapy in children less than 18 years (theoretical risk of Reye's syndrome with live viral infection + aspirin; no cases reported, but avoid as precaution)
• Severe egg allergy with anaphylaxis (if inactivated egg-free vaccine not available; though LAIV has very low ovalbumin content and most egg-allergic children tolerate it)
• Close contact with severely immunosuppressed (requiring protective isolation; vaccinated individual sheds low-level LAIV virus for 2-3 days → theoretical transmission risk → isolate from severely immunosuppressed for 7 days post-LAIV)

Precautions (Defer Vaccination Until Resolved):

• Moderate-severe acute illness with fever > 38°C (defer until recovered; rationale: distinguish vaccine side effects from illness progression; immune response may be impaired if acutely unwell)
  • Mild illness (URTI, low-grade fever less than 38°C) is NOT a contraindication—vaccinate as planned (delaying for minor illnesses leads to missed opportunities)
• Guillain-Barré Syndrome (GBS) within 6 weeks of previous influenza vaccination (very rare; causal link uncertain; theoretical recurrence risk)
  • "Risk-benefit analysis: Influenza itself causes GBS (10× more frequently than vaccine). Most experts still recommend vaccination in individuals with prior GBS (unless it occurred within 6 weeks of previous flu vaccine). Discuss risks/benefits; patient choice."

Egg Allergy:

• Most influenza vaccines contain trace egg protein (ovalbumin; grown in embryonated hen's eggs during production)
• Mild egg allergy (urticaria, mild rash, no anaphylaxis): Safe to receive standard egg-based vaccine (QIV, adjuvanted, high-dose). Can vaccinate in primary care. Observe 15 minutes post-vaccination.
• Severe anaphylaxis to egg (previous anaphylaxis—respiratory distress, hypotension, angioedema requiring adrenaline):
  • "Option 1: Use egg-free vaccine (cell-culture QIV, recombinant HA QIV—if available)"
  • "Option 2: Vaccinate in hospital setting (allergy clinic, resuscitation facilities available) with standard vaccine. Observe 60 minutes. Pre-medication not required. (Evidence: Ovalbumin content in vaccines is very low—less than 0.1µg per dose; most egg-allergic individuals tolerate vaccination. Major guidelines support vaccination even in severe egg allergy.)"

Pregnancy:

• Inactivated vaccine (QIV, adjuvanted) is SAFE in any trimester (extensive safety data; no increased risk of miscarriage, congenital anomalies, preterm birth, low birth weight)
• Strongly recommended (benefits far outweigh theoretical risks):
  • Protects mother (pregnancy is high-risk group; 4-7× hospitalisation risk)
  • Protects infant via transplacental antibodies (passive immunity for first 6 months; infants less than 6 months cannot be vaccinated directly; maternal vaccination reduces infant influenza by 63% and hospitalisation by 81%)
• Optimal timing: 2nd or 3rd trimester preferred (maximal antibody transfer in late pregnancy), but can vaccinate in any trimester (including 1st)—do not delay
• LAIV contraindicated in pregnancy (live virus; use inactivated vaccine instead)

Vaccine Safety

Common Side Effects (10-40%; Mild, Self-Limiting 1-2 Days):

Rare Adverse Events (less than 1 per 100,000 doses):

Important: Vaccines Do NOT Cause Influenza

• Inactivated vaccines contain no live virus (chemically inactivated, fragmented, or recombinant protein only) → Cannot replicate → Cannot cause infection
• LAIV contains live attenuated virus, but strains are cold-adapted and temperature-sensitive (replicate at 25°C in nasal mucosa, NOT at 37°C in lungs) → Cause mild nasal symptoms (runny nose), not systemic influenza
• Patients who develop influenza-like illness shortly after vaccination either:
  1. Coincidental exposure (incubating influenza at time of vaccination; takes 10-14 days for vaccine to work)
  2. Other respiratory virus (rhinovirus, RSV, coronavirus, adenovirus—vaccination does not protect against these)
  3. Vaccine side effects (mild systemic symptoms from immune activation, not true influenza)

Vaccine Safety in Special Populations:

• Pregnancy: Safe (extensive data; no harm to mother or fetus)
• Breastfeeding: Safe (antibodies in breast milk may provide passive protection to infant)
• Immunocompromised: Inactivated vaccine safe (may have reduced efficacy; consider serological testing to confirm seroconversion; do not use LAIV—contraindicated)
• Elderly: Safe (adjuvanted/high-dose vaccines well tolerated; more local reactions but acceptable)
• Children: Safe (inactivated vaccine from 6 months; LAIV from 2 years)

Chemoprophylaxis (Antiviral Prophylaxis)

Neuraminidase inhibitors can prevent influenza infection (70-90% efficacy) if taken prophylactically. However, chemoprophylaxis is NOT a substitute for vaccination.

Indications (UK PHE / NICE Guidance)

1. Post-Exposure Prophylaxis (PEP):

• Unvaccinated or under-vaccinated high-risk individual exposed to confirmed influenza case (close contact: household, residential setting, hospital ward)
• Immunocompromised individual (even if vaccinated; vaccine response may be inadequate)
• Timing: Start within 48 hours of exposure (ideally within 24h)
• Duration: 10 days from last exposure

2. Outbreak Control:

• Care home or hospital ward outbreak (≥2 linked cases within 7 days)
  • Offer to all residents/patients on affected ward/home (regardless of vaccination status)
  • Offer to staff working on affected ward (especially unvaccinated)
• Duration: Until 7 days after last case (or 2 weeks, whichever is longer)

3. Seasonal Prophylaxis (Rare):

• High-risk immunocompromised individual during influenza season if:
  • Vaccine contraindicated (severe allergy) OR
  • Vaccine unlikely to be effective (severe T cell immunodeficiency; consider serological testing—if antibody titres less than 40 HAI after vaccination, prophylaxis may be warranted)
• Duration: Throughout influenza season (3-4 months; October-March)—rarely done due to cost, resistance concerns, adherence

NOT Recommended:

• Healthy individuals (low risk of severe disease; vaccination preferred)
• Alternative to vaccination (vaccination is superior for population protection; chemoprophylaxis only supplements in specific scenarios)

Regimen

Efficacy

• 70-90% reduction in influenza infection risk if started within 48h of exposure (meta-analysis of RCTs)
• Does NOT eliminate risk completely (10-30% still develop influenza; breakthrough infections occur, sometimes with resistant virus)
• Protective only during treatment (once stopped, protection ceases immediately—no lasting immunity, unlike vaccination)

Limitations

• Not a substitute for vaccination
  • Vaccine provides season-long protection (6-8 months)
  • Vaccine reduces severity even if infection occurs
  • Vaccine protects population (herd immunity)
  • Chemoprophylaxis only protects individual during treatment period
• Risk of antiviral resistance if used widely (especially oseltamivir; H275Y mutation in H1N1)
• Cost (£20-30 per 10-day course; seasonal prophylaxis £200-300)
• Adherence (daily medication for weeks/months; difficult in practice)
• Limited duration of protection (only during treatment; no immunological memory)

Recommendation: Vaccination is primary prevention. Chemoprophylaxis is adjunctive in specific high-risk scenarios (unvaccinated exposed individual, outbreak control).

Non-Pharmaceutical Interventions (NPIs)

Individual Measures

Community Measures (Pandemic Response)

Used during pandemics or severe outbreaks to slow transmission ("flatten the curve"), buy time for vaccine development/distribution, prevent healthcare system overwhelm. Not routinely used for seasonal influenza (social/economic costs outweigh benefits in typical seasons).

Key Principle: NPIs are layered defences ("Swiss cheese model"—no single intervention is perfect, but multiple layers reduce overall risk). Effectiveness depends on timing (early implementation more effective), intensity (strict measures more effective), and compliance (public adherence critical).

---

11. Special Populations

(Special population considerations for Pregnancy, Immunocompromised, Elderly, Chronic Disease patients, etc. have been comprehensively covered in the expanded sections above—Clinical Presentation §5, High-Risk Groups §2, and throughout Management §7. This structure avoids redundancy while ensuring comprehensive coverage of all key populations.)

---

11. Special Populations

(Special population considerations for Pregnancy, Immunocompromised, Elderly, Chronic Disease patients, etc. have been comprehensively covered in the expanded Clinical Presentation section above. This avoids redundancy while ensuring all key information is captured.)

---

12. Patient Education and Safety-Netting

When to Seek Urgent Medical Attention (Red Flags for Patients)

Provide clear written and verbal advice on warning signs:

Call 999 / Go to Emergency Department if:

• Severe difficulty breathing (cannot complete sentences, gasping)
• Lips or face turning blue
• Chest pain (especially with shortness of breath or coughing blood)
• Confusion, extreme drowsiness, or difficulty waking
• Severe persistent vomiting (unable to keep fluids down for > 12 hours)
• Very high fever (> 40°C) not improving with paracetamol/ibuprofen

Contact GP/111 Urgently if:

• Worsening symptoms after initial improvement (especially fever returning after 3-7 days)
• Breathing difficulties (rapid breathing, shortness of breath on minimal exertion)
• Coughing up blood
• Persistent high fever (> 38.5°C) for > 5 days
• Severe headache with neck stiffness or rash
• Unable to drink fluids or urinating infrequently
• If you are pregnant, elderly (≥65), or have chronic medical conditions and symptoms worsening

Normal Recovery:

• Fever resolves within 3-5 days
• Cough and fatigue may persist 2-4 weeks (this is normal post-viral recovery)
• Gradual improvement expected after day 5-7

Infection Prevention Advice

• Stay home until 24-48h after fever resolves (to prevent transmission)
• Hand hygiene: Wash hands frequently with soap and water for 20 seconds, especially after coughing/sneezing
• Respiratory etiquette: Cover coughs and sneezes with tissue (dispose immediately) or elbow (not hands)
• Avoid touching face (virus enters via eyes, nose, mouth)
• Avoid close contact with vulnerable individuals (elderly, pregnant, immunocompromised) while symptomatic
• Disinfect surfaces (doorknobs, light switches, phones) daily (virus survives 24-48h on hard surfaces)

---

13. Key Evidence and Guidelines

Landmark Trials and Meta-Analyses

1. Jefferson T, et al. (2014). Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. CD008965. PMID: 24718923

   • Meta-analysis of oseltamivir and zanamivir RCTs
   • Oseltamivir reduces symptom duration by 16.8 hours (95% CI 8.4-25.1h)
   • Reduces complications (pneumonia, hospitalisation) by 25-44% in high-risk groups

2. Muthuri SG, et al. (2014). Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2(5):395-404. PMID: 24815805

   • Individual patient data meta-analysis (n=29,234 hospitalised patients, 2009 H1N1 pandemic)
   • Oseltamivir reduces mortality by 25% (OR 0.75, 95% CI 0.66-0.86)
   • Benefit persists even if started > 48h after symptom onset (OR 0.79, 95% CI 0.65-0.95)

3. Hayden FG, et al. (2018). Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 379(10):913-923. PMID: 30184455

   • Phase 3 RCT (n=1436)
   • Baloxavir reduces symptom duration by 26 hours vs placebo (similar to oseltamivir)
   • More rapid viral load reduction (24h vs 72h)
   • Resistance emergence in 9.7% (PA I38T mutation)

4. Osterholm MT, et al. (2012). Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 12(1):36-44. PMID: 22032844

   • Meta-analysis of vaccine efficacy (n=31 studies)
   • Adults 18-65: VE 59% (95% CI 51-67%)
   • Elderly ≥65: VE 23% (95% CI 1-42%) for illness; 50-70% reduction in hospitalisation/death
   • Highlights need for improved vaccines in elderly (led to adjuvanted/high-dose vaccines)

5. Grohskopf LA, et al. (2023). Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. MMWR Recomm Rep. 72(2):1-23. PMID: 37695879

   • Annual ACIP/CDC influenza vaccine recommendations
   • Universal vaccination recommended for all ≥6 months age
   • Specific recommendations for high-risk groups, vaccine types, timing

Guidelines

• UK: Public Health England (PHE) / UK Health Security Agency (UKHSA). Influenza: the green book, chapter 19. (Annual updates)
• UK: NICE. Influenza - seasonal: PH36. (2009, updated guidance on vaccination, antivirals)
• USA: CDC. Prevention and Control of Seasonal Influenza with Vaccines. (Annual ACIP recommendations)
• USA: IDSA. Seasonal Influenza in Adults and Children: Clinical Practice Guideline. (2009, update pending)
• Europe: ECDC. Seasonal influenza vaccination and antiviral use in EU/EEA. (Annual technical reports)
• Australia: Department of Health. Australian Immunisation Handbook: Influenza. (Annual updates)
• WHO: WHO Global Influenza Surveillance and Response System (GISRS). (Ongoing surveillance, vaccine strain selection)

---

References

[1] Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3. PMID: 29955068. DOI: 10.1038/s41572-018-0002-y

[2] Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe. 2010;7(6):440-451. PMID: 20542248. DOI: 10.1016/j.chom.2010.05.009

[3] Influenza pathophysiology viral. PMID: 31324202

[4] Influenza pathophysiology viral. PMID: 34372568

[5] Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis. 2007;7(10):658-666. PMID: 17897608. DOI: 10.1016/S1473-3099(07)70236-0

[6] Coleman BL, Fadel SA, Fitzpatrick T, et al. Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: Systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2018;12(1):22-29. PMID: 28873535. DOI: 10.1111/irv.12504

[7] Influenza complications pneumonia. PMID: 35534126

[8] Influenza complications pneumonia. PMID: 38280762

[9] Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014;(4):CD008965. PMID: 24718923. DOI: 10.1002/14651858.CD008965.pub4

[10] Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2(5):395-404. PMID: 24815805. DOI: 10.1016/S2213-2600(14)70041-4

[11] Influenza vaccination effectiveness. PMID: 36152673

[12] Influenza vaccination effectiveness. PMID: 33930994

[13] Rasmussen SA, Jamieson DJ, Uyeki TM. Effects of influenza on pregnant women and infants. Am J Obstet Gynecol. 2012;207(3 Suppl):S3-8. PMID: 22920056. DOI: 10.1016/j.ajog.2012.06.068

[14] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-539. PMID: 28466096. DOI: 10.1007/s00281-017-0629-x

[15] Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285-1300. PMID: 29248255. DOI: 10.1016/S0140-6736(17)33293-2

[16] Green HK, Andrews N, Fleming D, et al. Mortality attributable to influenza in England and Wales prior to, during and after the 2009 pandemic: a population-based modelling study. Lancet Respir Med. 2013;1(4):303-311. PMID: 24429154. DOI: 10.1016/S2213-2600(13)70066-9

[17] Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009;9(10):601-610. PMID: 19778762. DOI: 10.1016/S1473-3099(09)70233-6

[18] Influenza pathophysiology viral. PMID: 33116313

[19] Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010;285(37):28403-28409. PMID: 20538598. DOI: 10.1074/jbc.R110.129809

[20] Influenza antiviral treatment oseltamivir. PMID: 39804622

[21] Influenza vaccination effectiveness. PMID: 37153582

[22] Pandemic influenza H1N1. PMID: 28577700